Pathogenic autoreactive effector T-cell clones (Autoreactive Teff)

Pathogenic autoreactive effector T-cell clones are specialized populations of T-lymphocytes that have bypassed immune tolerance mechanisms to recognize and attack self-antigens. These cells are the primary drivers of tissue damage in various autoimmune conditions, including type 1 diabetes, multiple sclerosis, and rheumatoid arthritis, where they orchestrate chronic inflammatory responses (Walker & Abbas, 2002). They are characterized by specific T-cell receptor (TCR) sequences and the secretion of pro-inflammatory cytokines such as interferon-gamma and interleukin-17 (Rosenblum et al., 2015). Pharmacological intervention typically involves broad immunosuppression or more targeted approaches like anti-CD3 antibodies (e.g., Teplizumab) which aim to deplete or exhaust these pathogenic clones (Herold et al., 2019). Modern therapeutic research is increasingly focused on antigen-specific therapies, such as peptide-MHC complexes or CAR-Treg cells, designed to selectively neutralize these clones without compromising the rest of the immune system (Bluestone et al., 2010). These cells often exhibit an activated phenotype, expressing markers like CD25 and HLA-DR, which distinguish them from naive or regulatory T-cell subsets. The persistence of these clones is often linked to defects in peripheral tolerance or the failure of regulatory T-cells to suppress their activity.

Other names

Autoreactive T-cellsSelf-reactive T-cellsPathogenic T-cellsAutoreactive T-lymphocytesEffector T-cells (autoimmune)

T-cell depletion, costimulation blockade, calcineurin inhibition, S1P receptor modulation, and integrin alpha-4 inhibition.